Against the backdrop of the Belgian EU Council Presidency, the Rare Diseases Forum 2024 brings together senior leaders from across patient organisations, industry and policy to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda.
About
‘The Rare Diseases Forum 2024: Securing Europe’s Competitiveness in R&D for people living with rare diseases’ features keynotes and panel discussions with a focus on the EU’s role in enhancing competitiveness in life sciences, fostering investment in the rare diseases sector, and examining the benefits of a competitive agenda for those with rare diseases.
The event is convened by Global Counsel on behalf of the forum partners, EURORDIS, RaDiOrg, EFPIA, Eucope, EuropaBio, Pharma.be, UCB, Novo Nordisk, Sanofi & Takeda.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.